Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

Background/Objectives: Dose reductions in CDK4/6 inhibitors, such as ribociclib and palbociclib, are often necessary due to treatment-related toxicities in patients with advanced breast cancer. This study aims to evaluate the impact of the timing of dose reductions on progression-free survival (PFS)...

Full description

Saved in:
Bibliographic Details
Main Authors: Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Current Oncology
Subjects:
CDK4/6 inhibitors
breast cancer
dose reduction
survival outcomes
Online Access:https://www.mdpi.com/1718-7729/31/12/548
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items